Dr gavidel journal club govaresh

2. Drgavidel journal club govaresh

3. liver cancers are the fourth most common cause of cancer-related death and rank sixth in terms of incident case With a 5-year survival of 18%, liver cancer is the second most lethal tumor, after pancreatic cancer mostly as a result of hepatitis B or C virus (HBV or HCV) infection or alcohol abuse

4. nonalcoholic fatty liver disease (NAFLD), which together with metabolic syndrome and obesity amplifies the risk of liver cancer, will soon become a leading cause of liver cancer in Western countries Racial or ethnic group diftferences : with blacks and Hispanics less likely than whites to undergo curative therapies

9. sustained hepatic inflammation Fibrosis aberrant hepatocyte regeneration Cirrhosis HCC Dysplastic nodules

10. Hepatocellular carcinoma can also arise in patients who have chronic liver disease but do not have established cirrhosis or marked inflammation (e.g., patients with HBV infection).

12. Patients with hepatocellular carcinoma at the same clinical stage can have different molecular subtypes have not been thoroughly tested as predictors of a response to systemic therapies, which has limited their clinical usefulness

14. Hepatocellular carcinoma is among the solid cancers with the fewest somatic mutations that can be targeted with molecular therapies no mutation is used in clinical practice to predict a therapeutic response. High-level DNA amplifications located in chromosome 6p21 and 11q13, the respective loci for VEGFA and CCND1/FGF19, could also be targeted with molecular therapies, but their prevalence is low.

16. rare among patients without liver disease twice as common in men as in women Cirrhosis of any cause annual : incidence between 2 and 4%. This risk varies according to cause, geographic area, sex, age, degree of liver damage

17. Worldwide, HBV infection is the main cause of hepatocellular carcinoma. Dietary exposure to aflatoxin B1 amplifies the risk of hepatocellular carcinoma among patients with HBV infection, through a specific mutation in TP53 at position 249 (R→S)

18. In Western countries and Japan, the main cause of hepatocellular carcinoma is HCV infection The incidence of hepatocellular carcinoma due to NAFLD is increasing worldwide Alcoholic cirrhosis is another frequent cause of hepatocellular carcinoma. Smoking and coinfection with the human immunodeficiency virus can also contribute to the development of hepatocellular carcinoma.

19. HBV infection has a direct oncogenic effect, regardless of the degree of underlying liver fibrosis but hepatocellular carcinoma rarely occurs in HCV-infected patients who do not have advanced fibrosis

20. Antiviral therapies are effective in reducing the incidence of hepatocellular carcinoma but do not eradicate the risk Apart from treatment of the cause of the liver disease, no drugs are known to reduce the incidence of hepatocellular carcinoma.

22. Patients with cirrhosis and advanced liver dysfunction, who would not be eligible for a curative treatment, are not candidates for surveillance. This does not apply to candidates for liver transplantation as a result of liver dysfunction

23. The risk of hepatocellular carcinoma among patients with chronic HBV infection varies across geographic regions (with higher risks in Africa and Asia than in other regions) increases with age male sex presence of liver fibrosis high level of viral replication genotype C family history of hepatocellular carcinoma.

24. Patients with chronic HCV infection and advanced fibrosis, defined by the Mettavir system as a score of F3 or higher on a scale of F0 to F4, with higher scores indicating more severe fibrosis

25. Until there are methods available to identify patients who are at increased risk, surveillance is not recommended for patients who have NAFLD without cirrhosis

26. Abdominal ultrasonography every 6 months is the recommended method for surveillance with or without measurement of serum levels of alpha-fetoprotein

28. because of the vascular shift that occurs during malignant transformation of hepatocytes, in which benign lesions (e.g., regenerative and dysplastic nodules) are supplied by branches of the portal system, whereas malignant nodules are supplied by blood from the hepatic artery. This shift translates into a distinctive pattern of hyperenhancement in the arterial phase and washout in venous or delayed phases on contrast-enhanced CT or MRI. This pattern has a sensitivity between 66% and 82% and a specificity higher than 90% for the diagnosis of hepatocellular carcinoma in patients with cirrhosis and nodules larger than 1 cm in diameter.

30. Establishing a histologic diagnosis in a patient with small nodules can be challenging, but a set of immunostaining m glypigan 3 heat shock protein 70 glutamine synthetase — increase diagnostic accuracy. Patients who have cirrhosis with nodules that are less than 1 cm in diameter should undergo ultrasound surveillance every 3 to 4 months and be considered for a return to conventional surveillance if the nodule is stable in size after 12 months

33. complexity in the management of hepatocellular carcinoma calls for a multidisciplinary approach, with ex-pertise in hepatology, hepatobiliary surgery, pa-thology, oncology, radiology (both diagnostic and interventional), and specialized nursing

36. The ideal candidates for resection are patients with a solitary tumor at an early stage (BCLC stage 0 or A) regardless of tumor size in whom the performance status is good liver function is well preserved there is no clinically significant portal hypertension survival above 60% at 5 years,

37. The main method is image-guided, percutaneous radiofrequency ablation, which achieves tumor necrosis by inducing a high intratumoral temperature. The extent of tumor necrosis is negatively correlated with tumor size and drops significantly in tumors larger than 3 cm in diameter Other ablative options include microwave ablation Cryoablation ethanol injection

38. intermediate-stage tumors (BCLC stage B) should be considered for transarterial therapies TACE should not be considered in patients with decompensated cirrhosis. use of drug-eluting beads has antitumoral activity similar to that of conventional TACE, with fewer side effects, whereas the use of bland embolization is more controversial Median survival with TACE ranges from 26 to 40 months, depending on patient selection

39. Selective internal radiation therapy (SIRT) in patients with BCLC stage B tumors based on the intraarterial infusion of microspheres with the radioisotope yttrium-90. Unlike TACE, SIRT does not include a macroembolic step. No randomized phase 3 trials have compared TACE and SIRT with respect to survival, but numerous cohort and retrospective studies indicate that SIRT is a safe procedure with an objective response similar to that seen with TACE

40. Sorafenib was the first systemic drug approved by (FDA) for the treatment of hepatocellular carcinoma and is the standard of care for frontline therapy Lenvatinib, another inhibitor of multiple kinases, showed antitumoral activity in a noninferiority trial. Median survival was 13.6 months with lenvatinib and 12.3 months with sorafenib. adverse events with lenvatinib included hyperrtension, decreased weight palmar–plantar erythrodysesthesia Lenvatinib received FDA approval in 2018.

41. Regorafenib, also an inhibitor of multiple kinases, increased survival, as compared with placebo, from 7.8 to 10.6 months among patients with tumor progression during treatment with sorafenib. With a safety profile similar to that of sorafenib, regorafenib decreased the risk of death by 37%, as compared with placebo, and became the first drug approved by the FDA for second-line treatment.

42. Cabozantinib, an inhibitor of receptor tyrosine kinases, including VEGFR, MET, and AXL, reduced the risk of death, as compared with placebo Ramucirumab, an antibody against VEGF receptor 2 improved survival, as compared with placebo

44. Impact of coffee on HCC development • Numerous epidemiological studies have addressed the preventionof HCC in patients with chronic liver disease • Trials analyzing the effect of coffee consumption have shown a consistently positive effect with regard to lowering HCC incidence Level of evidence Grade of recommendation EASL CPG HCC. J Hepatol 2018; doi: 10.1016/j.jhep.2018.03.019

48. Algorithm for diagnosis and recall in cirrhotic liver Mass/nodule at imaging <1 cm >1 cm Multiphasic contrast-enhanced CT or MRI,* or gadoxetic-enhanced MRI† Repeat US at 4 months Stable‡ Growing/changingpattern 1 positive technique:HCC imaging hallmarks No Yes ‖ Use other modality: multiphasic contrast-enhanced CT or MRI,* or gadoxetic-enhanced MRI,†or contrast-enhanced ultrasound§ Biopsy unclear: Consider re-biopsy 1 positive technique: HCC imaging hallmarks No Yes Non-HCC malignancy/ benign Biopsy HCC *Using extracellular MRI contrast agents or gadobenatedimeglumine; †Diagnostic criteria: APHE and washout on the portal venous phase; ‡Lesion <1 cm stable for 12 months (three controls after 4 months) can be shifted back to regular 6-month surveillance; §Diagnostic criteria: APHE and mild washout after 60 seconds; ‖Optional for centre-based programmes EASL CPG HCC. J Hepatol 2018; doi: 10.1016/j.jhep.2018.03.019